Nesfatin-1 Level in Patients With Type 2 Diabetes, Insulin Resistance and Obesity

Determination of the Relationship Between Nesfatin-1 Levels and Energy Intake Levels of Patients With Type 2 Diabetes, Insulin Resistance and Obesity

This research was planned to determine the level of nesfatin-1, known as satiety hormone, in type 2 diabetes, insulin diabetes and obesity patients and to determine whether there is a relationship between patients' energy intake levels. Additionally, it was aimed to evaluate the relationship between patients' nesfatin-1 values and serum glucose, insulin, lipid concentrations.

Nesfatin-1 levels of patients with type 2 diabetes, insulin resistance and obesity will be measured. In addition, patients' daily food consumption will be taken and the amount of energy they receive will be calculated daily. The relationship between the level of nesfatin-1 in the blood and the energy received will be examined.

Inclusion Criteria:

• Type 2 diabetes
• Insulin resistance
• Obesity disease

Exclusion Criteria:

• Pediatric individuals
• All patients who are hospitalized,
• Liver disease
• Cancer patients
• Disease related to the gastrointestinal tract
• Nephrological disease such as chronic kidney failure, acute kidney failure, nephrotic syndrome
• Neurological disease